The Motley Fool

Why GlaxoSmithKline plc, Telecom plus PLC and Kentz Corporation Limited Should Beat The FTSE 100 Today

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

The FTSE 100 (FTSEINDICES: ^FTSE) ended yesterday with a 25-point loss, and it’s started today with a further dip of 16 points to 6,682 after ITV shares were downgraded following on from yesterday’s third-quarter update. But the index of top UK shares is only down 11 points on the week so far, and has gained 13% since the start of 2013 — could we be in for a late December surge to push us closer to that record 6,876 level from May?

There’s very little news of individual shares today, but here are three from the various indices that look set to beat the FTSE:

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

GlaxoSmithKline

Shares in GlaxoSmithKline (LSE: GSK) (NYSE:GSK.US) picked up 9.3p (0.6%) in early trading — not a big rise, but still welcome on a day when the FTSE is falling.

The news today is that the pharmaceuticals giant has completed the sale of part of its stake in Aspen Pharmacare Holdings, having agreed the sale of 28.2 million shares at a price of 250 rand per share. Following the sale, which will net about £425m, Glaxo will sill hold 56.5 million Aspen shares, or 12.4% of the company.

Glaxo shares have been erratic since the Spring, but they’re up around 22% over the past 12 months.

Telecom plus

We need to look outside the FTSE 100 for bigger rises today, and we see Telecom plus shares up a very nice 226p (15%) to 1,733p after the multi-utilities supplier released interim figures and announced an acquisition and share placing.

First-half revenue climbed 17% to £245.8m, with pre-tax profit up 10.1% to £13.7m. Adjusted earnings per share gained 11.5% to 15.5p, and the interim dividend was lifted 23% to 16p per share. These nice figures were made possible by a rise in customer numbers of 33,908, to 494,940.

Telecom Plus has also conditionally agreed to acquire Electricity Plus Supply and Gas Plus Supply from Npower, for a total price of £218m. The deal will be funded by a combination of a new share issue and £100m of borrowing, and will get Telecom plus a 20-year energy-supply deal.

Kentz Corporation

Our third riser for today is Kentz Corporation (LSE: KENZ), whose shares put on 16p (2.9%) to 558p after the company announced a $190m engineering contract with Qatar Petroleum for well-head control systems and corrosion protection for approximately 775 wells in the Dukhan Oilfield in Qatar.

Kentz shares have climbed strongly since the summer, and are now 47% ahead over the past 12 months.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

> Alan does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.